Clinical Trial Detail

NCT ID NCT02117362
Title Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Providence Health & Services
Indications

melanoma

Therapies

Ipilimumab

Belapectin

Age Groups: adult

No variant requirements are available.